The Fox Chase Chemical Diversity Center Announces that the FDA has Completed its Review of FC-4157 (also known as BHV-4157) Investigational New Drug Application (IND) Filed on May 31, 2016 by Biohaven Pharmaceutical Holding Company Ltd
Doylestown, PA. July 5, 2016- FCCDC is pleased to announce that the U.S. Food and Drug Administration (FDA) has completed its review of the FC-4157 (also known as BHV-4157) investigational new drug application (IND) filed on May 31, 2016 by Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”), and informed Biohaven that clinical trials in humans may proceed, as noted on Yahoo Finance (see here). FC-4157 was first prepared at FCCDC by work funded by SBIR grants from the National Institutes of Health (R44CA156781), and is currently being developed by Biohaven for multiple indications.